Gilead sees 38% U.S. Medicare price cut for Biktarvy from Jan. 1, 2028, trimming 2028 sales by ~ $1.5B

 

• Q3 2026 revenue was $8.3B, up 7% YoY, beating Zacks estimates and Wall Street forecasts by nearly $500 million.
• Q3 2026 product sales increased 13% to $8.3 billion, as reported by Gilead Sciences.
• Non-GAAP EPS for Q3 2026 was $2.55, up 3% year over year and above Zacks earnings estimates.
• New 2026 sales outlook of $31.1–$31.3 billion is about $900 million above the prior midpoint.
• Gilead also raised its full-year 2026 base business revenue guidance.
• Quarterly beat was driven by the HIV franchise and cancer drug Trodelvy, while other business areas lagged.

https://finviz.com/stock?t=GILD&p=d